Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026
Business Wire•04/11/2026•09:00 ET
0
Key Highlights
- ➤30+ ASH abstracts will showcase Incyte’s hematology portfolio progress
- ➤INCA033989 showed robust spleen, symptom, and anemia responses in first-line MF
- ➤INCA033989 produced molecular responses and restored normal hematopoiesis in ET
- ➤Latarcibart long-term Phase 1/2 data will assess prophylaxis in VWD
- ➤ASH data will be discussed at Incyte’s December 12 investor webcast
Expert Statements
Pablo J. Cagnoni, President, Incyte and Global Head of Research and Development
“Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions”
Pablo J. Cagnoni, President, Incyte and Global Head of Research and Development
“We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients.”
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compounds
Get started
Create a free account to read the full story.